| Market Capitalization (Millions $) |
184 |
| Shares
Outstanding (Millions) |
50 |
| Employees |
139 |
| Revenues (TTM) (Millions $) |
43 |
| Net Income (TTM) (Millions $) |
-32 |
| Cash Flow (TTM) (Millions $) |
152 |
| Capital Exp. (TTM) (Millions $) |
0 |
Genfit S A
Genfit S is a biopharmaceutical company that specializes in the development of innovative therapies for patients with metabolic and liver-related diseases.
The company's lead product candidate is elafibranor, which is a first-in-class drug being developed for the treatment of non-alcoholic steatohepatitis (NASH).
NASH is a chronic and progressive liver disease that is associated with obesity, insulin resistance, and other metabolic disorders.
Genfit S is headquartered in France and has a strong pipeline of other innovative products in development.
The company has a proprietary technology platform that allows it to develop drugs that can modulate the activity of nuclear receptors, which are important regulators of gene expression and metabolism.
The company has a team of experienced scientists and researchers who are dedicated to the development of safe and effective therapies for patients with liver and metabolic diseases.
Genfit S has established numerous partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies to advance its research and development efforts.
Overall, Genfit S is a promising biopharmaceutical company that is leading the way in the development of innovative therapies for patients with liver and metabolic diseases.
Its expertise in nuclear receptor modulation and strong pipeline of products makes it a company to watch in the biotech space.
Company Address: 885, avenue Eug?ne Avinée Loos 59120
Company Phone Number: 2016 4000 Stock Exchange / Ticker: NASDAQ GNFT
|
1.93% 